Equidacent
Bevacizumab biosimilar developed by Centus Biotherapeutics (Fujifilm Kyowa Kirin and AstraZeneca), development code FKB238. Reference product Avastin.
Brands by market: Equidacent (EU, withdrawn) · Commercial partner or holder: Centus Biotherapeutics · Company profile
FDANot listed
EMAWithdrawn
MHRANot listed
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Not yet approved in any of the 7 markets
Connections
About Equidacent
Equidacent was a bevacizumab developed by Centus Biotherapeutics, a joint venture between Fujifilm Kyowa Kirin and AstraZeneca. It was approved in Europe in 2020 and later withdrawn by the holder without launching. It has no approval in any other market.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Equidacent
European Medicines Agency and European CommissionWithdrawnBrand
Equidacent
Holder or applicant
Centus Biotherapeutics Europe Limited
Pathway
Centralised (Article 10(4))
Approved
Sep 2020
Application or permission
EMEA/H/C/005181
Withdrawn
date not published
Presentations
see SmPC
Remarks
Withdrawn by the holder; date not published in the EMA table.
Source
S017 (EMA) · checked Sep 2026
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning bevacizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.